FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028937577> ?p ?o ?g. }

• W2028937577 endingPage "558" @default.
• W2028937577 startingPage "552" @default.
• W2028937577 abstract "The aim of this open label phase II study (NCT00407459) was to assess the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM).Eligible patients received pemetrexed 500 mg m(-2), carboplatin area under the plasma concentration-time curve (AUC) 5 mg ml(-1) per minute and bevacizumab 15 mg kg(-1), administered intravenously every 21 days for six cycles, followed by maintenance bevacizumab. The primary end point of the study was progression-free survival (PFS). A 50% improvement in median PFS in comparison with standard pemetrexed/platinum combinations (from 6 to 9 months) was postulated.Seventy-six patients were evaluable for analysis. A partial response was achieved in 26 cases (34.2%, 95% CI 23.7-46.0%). Forty-four (57.9%, 95% CI 46.0-69.1%) had stable disease. Median PFS and overall survival were 6.9 and 15.3 months, respectively. Haematological and non-haematological toxicities were generally mild; however, some severe adverse events were reported, including grade 3-4 fatigue in 8% and bowel perforation in 4% of patients. Three toxic deaths occurred.The primary end point of the trial was not reached. However, due to the limitation of a non-randomised phase II design, further data are needed before drawing any definite conclusion on the role of bevacizumab in MPM." @default.
• W2028937577 created "2016-06-24" @default.
• W2028937577 creator A5011118091 @default.
• W2028937577 creator A5018858868 @default.
• W2028937577 creator A5019376695 @default.
• W2028937577 creator A5032477448 @default.
• W2028937577 creator A5036696968 @default.
• W2028937577 creator A5046939478 @default.
• W2028937577 creator A5047170696 @default.
• W2028937577 creator A5051919018 @default.
• W2028937577 creator A5053651576 @default.
• W2028937577 creator A5055283283 @default.
• W2028937577 creator A5059424755 @default.
• W2028937577 creator A5062532607 @default.
• W2028937577 creator A5063509465 @default.
• W2028937577 creator A5069416473 @default.
• W2028937577 creator A5070833456 @default.
• W2028937577 creator A5071783009 @default.
• W2028937577 creator A5082045927 @default.
• W2028937577 creator A5082515771 @default.
• W2028937577 date "2013-07-16" @default.
• W2028937577 modified "2023-10-18" @default.
• W2028937577 title "Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma" @default.
• W2028937577 cites W1971211622 @default.
• W2028937577 cites W1977062776 @default.
• W2028937577 cites W1978327177 @default.
• W2028937577 cites W1992112921 @default.
• W2028937577 cites W1993016882 @default.
• W2028937577 cites W2009337734 @default.
• W2028937577 cites W2014943535 @default.
• W2028937577 cites W2030133029 @default.
• W2028937577 cites W2042884540 @default.
• W2028937577 cites W2048946249 @default.
• W2028937577 cites W2054673942 @default.
• W2028937577 cites W2060281755 @default.
• W2028937577 cites W2060447671 @default.
• W2028937577 cites W2061650454 @default.
• W2028937577 cites W2065144267 @default.
• W2028937577 cites W2067583075 @default.
• W2028937577 cites W2095824051 @default.
• W2028937577 cites W2097463411 @default.
• W2028937577 cites W2100576484 @default.
• W2028937577 cites W2101834873 @default.
• W2028937577 cites W2102627969 @default.
• W2028937577 cites W2108923852 @default.
• W2028937577 cites W2129967236 @default.
• W2028937577 cites W2134707435 @default.
• W2028937577 cites W2139675556 @default.
• W2028937577 cites W2145180354 @default.
• W2028937577 cites W2148716917 @default.
• W2028937577 cites W2152998633 @default.
• W2028937577 cites W2153109178 @default.
• W2028937577 cites W2167527173 @default.
• W2028937577 cites W2169833424 @default.
• W2028937577 cites W2209671128 @default.
• W2028937577 cites W2249322187 @default.
• W2028937577 cites W4293241248 @default.
• W2028937577 cites W4296217589 @default.
• W2028937577 doi "https://doi.org/10.1038/bjc.2013.368" @default.
• W2028937577 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3738125" @default.
• W2028937577 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23860535" @default.
• W2028937577 hasPublicationYear "2013" @default.
• W2028937577 type Work @default.
• W2028937577 sameAs 2028937577 @default.
• W2028937577 citedByCount "84" @default.
• W2028937577 countsByYear W20289375772013 @default.
• W2028937577 countsByYear W20289375772014 @default.
• W2028937577 countsByYear W20289375772015 @default.
• W2028937577 countsByYear W20289375772016 @default.
• W2028937577 countsByYear W20289375772017 @default.
• W2028937577 countsByYear W20289375772018 @default.
• W2028937577 countsByYear W20289375772019 @default.
• W2028937577 countsByYear W20289375772020 @default.
• W2028937577 countsByYear W20289375772021 @default.
• W2028937577 countsByYear W20289375772022 @default.
• W2028937577 countsByYear W20289375772023 @default.
• W2028937577 crossrefType "journal-article" @default.
• W2028937577 hasAuthorship W2028937577A5011118091 @default.
• W2028937577 hasAuthorship W2028937577A5018858868 @default.
• W2028937577 hasAuthorship W2028937577A5019376695 @default.
• W2028937577 hasAuthorship W2028937577A5032477448 @default.
• W2028937577 hasAuthorship W2028937577A5036696968 @default.
• W2028937577 hasAuthorship W2028937577A5046939478 @default.
• W2028937577 hasAuthorship W2028937577A5047170696 @default.
• W2028937577 hasAuthorship W2028937577A5051919018 @default.
• W2028937577 hasAuthorship W2028937577A5053651576 @default.
• W2028937577 hasAuthorship W2028937577A5055283283 @default.
• W2028937577 hasAuthorship W2028937577A5059424755 @default.
• W2028937577 hasAuthorship W2028937577A5062532607 @default.
• W2028937577 hasAuthorship W2028937577A5063509465 @default.
• W2028937577 hasAuthorship W2028937577A5069416473 @default.
• W2028937577 hasAuthorship W2028937577A5070833456 @default.
• W2028937577 hasAuthorship W2028937577A5071783009 @default.
• W2028937577 hasAuthorship W2028937577A5082045927 @default.
• W2028937577 hasAuthorship W2028937577A5082515771 @default.
• W2028937577 hasBestOaLocation W20289375771 @default.
• W2028937577 hasConcept C126322002 @default.
• W2028937577 hasConcept C141071460 @default.

• next